Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT06896916 · readout ≤ 3,512 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
135estimated
Sites
27
Countries
Australia, Canada, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-07 | actual | When the study began enrolling |
| Primary completion | Mar 2036 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Etentamig
- Drug: Iberdomide
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
measured Up to Approximately 56 Days
Number of Participants with Adverse Events (AE)s
measured Up to Approximately 129 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed